Recent Advance in Antibody–Drug Conjugates for Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 130
Special Issue Editor
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are engineered compound therapeutics consisting of monoclonal antibodies against tumor-associated antigens, to which highly potent cytotoxic reagents are conjugated with chemical linkers. The strategy conveying ADCs couples the precision of the antibody targeting group with the cytocidal activity of the cytotoxic reagent, which is generally more toxic on its own, for dispensation by systemic administration. In this manner, ADCs are expected to reduce off-target toxicities in patients by limiting the exposure of normal tissues to the payload compared with treatment via systemic chemotherapy. This Issue approaches the development of ADCs via the angles of antibody development, intracellular trafficking of antibodies, anti-cancer reagents and chemical linker selection with site-specific conjugation to antibodies.
To this end, this special issue aims to serve as a reference volume for ADCs and give readers a comprehensive understanding of them, exploring and explaining each ADC component (monoclonal antibody, linker group and cytotoxic payload) individually and offering a brief future perspective on the research field of ADCs.
Prof. Dr. Taketo Yamada
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ADCs
- antibody–drug conjugates
- monoclonal antibodies
- chemical linker
- cell surface targets
- payload
- cytotoxic reagents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
